Cowen always deemed CELG’s failed drug a risky contender, welcomes GILD’s full approval for Yescarta.
Did this $4 billion fund make the right call on these two soaring biotechs?
Gilead Sciences, Inc. (NASDAQ:GILD) announced detailed 48-week results from a Phase 3 study (Study 1878) evaluating …
Gilead Sciences, Inc. (NASDAQ:GILD) announced that the China Food and Drug Administration (CFDA) has approved …
Analyst questions the bigger picture for GILD, including risks and visibility challenges wavering in 2018.
Gilead is very confident on the successful commercial launch of Axi-Cel.
Kite acquisition signals Gilead’s leadership and continued consolidation moving forward, says Katherine Xu
How Do Biotech’s Movers and Shakers Fare Under Puravida Funds’ Healthcare-Centric Trading Strategy?
Gilead Pivots to Cell Therapy; Cowen’s Phil Nadeau Weighs in
How Has a Deal Between Kite and Gilead Likewise Sent Juno Shares Jumping?